Department of Epidemiology and Public Health, University College London, London, UK.
Department of Public Health Clinicum, University of Helsinki, Helsinki, Finland.
Alzheimers Dement. 2022 Apr;18(4):612-624. doi: 10.1002/alz.12419. Epub 2021 Aug 2.
Plasma proteins affect biological processes and are common drug targets but their role in the development of Alzheimer's disease and related dementias remains unclear. We examined associations between 4953 plasma proteins and cognitive decline and risk of dementia in two cohort studies with 20-year follow-ups.
In the Whitehall II prospective cohort study proteins were measured using SOMAscan technology. Cognitive performance was tested five times over 20 years. Linkage to electronic health records identified incident dementia. The results were replicated in the Atherosclerosis Risk in Communities (ARIC) study.
Fifteen non-amyloid/non-tau-related proteins were associated with cognitive decline and dementia, were consistently identified in both cohorts, and were not explained by known dementia risk factors. Levels of six of the proteins are modifiable by currently approved medications for other conditions.
This study identified several plasma proteins in dementia-free people that are associated with long-term risk of cognitive decline and dementia.
血浆蛋白影响生物过程，是常见的药物靶点，但它们在阿尔茨海默病及相关痴呆的发展中的作用仍不清楚。我们在两项具有 20 年随访的队列研究中，研究了 4953 种血浆蛋白与认知能力下降和痴呆风险之间的关系。
在 Whitehall II 前瞻性队列研究中，使用 SOMAscan 技术测量蛋白质。在 20 年内进行了五次认知能力测试。通过电子健康记录确定是否发生痴呆。结果在动脉粥样硬化风险社区（ARIC）研究中得到了复制。
有 15 种非淀粉样蛋白/非tau 相关蛋白与认知能力下降和痴呆有关，在两个队列中均得到一致识别，且不能用已知的痴呆风险因素来解释。其中六种蛋白质的水平可以通过目前批准用于治疗其他疾病的药物来调节。
本研究在无痴呆人群中发现了几种与长期认知能力下降和痴呆风险相关的血浆蛋白。
Zotero 插件
